Prophylactic Effects of a Fixed Dorsolamide/Timolol Combination on IOP Elevation before Intravitreal Anti-VEGF Injection.
10.3341/jkos.2011.52.6.702
- Author:
Young Jin LIM
1
;
Jong Myong KIM
;
Yong Seop HAN
;
In Young CHUNG
;
Jong Moon PARK
Author Information
1. Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea. medcabin@hanmail.net
- Publication Type:Clinical Trial ; Original Article ; Randomized Controlled Trial
- Keywords:
Bevacizumab;
Dorsolamide;
IOP;
Ranibizumab;
Timolol
- MeSH:
Antibodies, Monoclonal, Humanized;
Eye;
Humans;
Intraocular Pressure;
Intravitreal Injections;
Prospective Studies;
Timolol;
Bevacizumab;
Ranibizumab
- From:Journal of the Korean Ophthalmological Society
2011;52(6):702-708
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of the present study was to investigate the prophylactic effects of a fixed combination of dorsolamide/timolol on intraocular pressure (IOP) elevation before intravitreal anti-VEGF injection. METHODS: A prospective, randomized clinical trial was conducted on 91 eyes of 91 patients undergoing intravitreal anti-VEGF injection. The eyes were randomly divided into 2 groups, the eyes which had used the fixed prophylactic dorsolamide/timolol combination (group 1, 58 eyes) and the eyes which had not used the combination (group 2, 15 eyes). The IOP was measured one hour and 5 minutes prior to the procedure, 5 minutes interval up to 30 minutes after the procedure and one hour, 1 day, 7 days, and one month after the procedure. The IOP changes were analyzed. RESULTS: The mean 5 minutes and 30 minutes postoperative IOPs were 14.12 +/- 4.18 mm Hg and 10.87 +/- 1.58 mm Hg in group 1 and 28.21 +/- 3.16 mm Hg and 17.48 +/- 2.34 mm Hg in group 2, respectively. After IVBI, the mean 5 min postoperative IOP was 12.17 +/- 1.13 mm Hg in group 1 and 27.12 +/- 3.35 mm Hg in group 2. After IVRI, the mean 5 minutes postoperative IOP was 15.98 +/- 4.14 mm Hg in group 1 and 25.19 +/- 1.04 mm Hg in group 2. CONCLUSIONS: Prophylactic use of a fixed dorsolamide/timolol combination before intravitreal anti-VEGF injection is an easy and safe method of preventing IOP elevation immediately after intravitreal injection of bevacizumab or ranibizumab.
